Can Inhibiting Dihydropyrimidine Dehydrogenase Limit Hand-Foot Syndrome Caused by Fluoropyrimidines?YEN-REVOLLO, Jane L; GOLDBERG, Richard M; MCLEOD, Howard L et al.Clinical cancer research. 2008, Vol 14, Num 1, pp 8-13, issn 1078-0432, 6 p.Article

Validation of 24-Hour Flucytosine MIC Determination by Comparison with 48-Hour Determination by the Clinical and Laboratory Standards Institute M27-A3 Broth Microdilution Reference MethodLOCKHART, Shawn R; BOLDEN, Carol B; IQBAL, Naureen et al.Journal of clinical microbiology (Print). 2011, Vol 49, Num 12, pp 4322-4325, issn 0095-1137, 4 p.Article

Inappropriate continuation of medication when patients are admitted acutely: the example of capecitabineBOOTH, J. A; BOOTH, C; CRAWFORD, S. Michael et al.Clinical medicine. 2011, Vol 11, Num 5, issn 1470-2118, p. 511Article

Phase IB Study of the mTOR Inhibitor Ridaforolimus With CapecitabinePEROTTI, Antonella; LOCATELLI, Alberta; ALBANELL, Joan et al.Journal of clinical oncology. 2010, Vol 28, Num 30, pp 4554-4561, issn 0732-183X, 8 p.Article

The use of FUdR can cause prolonged longevity in mutant nematodesAITLHADJ, Layla; STÜRZENBAUM, Stephen R.Mechanisms of ageing and development. 2010, Vol 131, Num 5, pp 364-365, issn 0047-6374, 2 p.Article

Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine unitsTANABE, Kazuhito; SUGIURA, Masaaki; ITO, Takeo et al.Bioorganic & medicinal chemistry. 2012, Vol 20, Num 17, pp 5164-5168, issn 0968-0896, 5 p.Article

Toxicité sévère à la capécitabine liée à un déficit enzymatique en dihydropyrimidine déshydrogénase (DPD) = Severe toxicity following capecitabine administration because of dihydropyrimidine deshydrogenase (DPD) deficiencyCOURSIER, S; MARTELET, S; GUILLERMET, A et al.Gastroentérologie clinique et biologique. 2010, Vol 34, Num 3, pp 218-223, issn 0399-8320, 6 p.Article

A Dynamic Model of Hand-and-Foot Syndrome in Patients Receiving CapecitabineHENIN, E; YOU, B; TOD, M et al.Clinical pharmacology and therapeutics. 2009, Vol 85, Num 4, pp 418-425, issn 0009-9236, 8 p.Article

Fluorodeoxyuridine affects the identification of metabolic responses to daf-2 status in Caenorhabditis elegansDAVIES, Sarah K; LEROI, Armand M; BUNDY, Jacob G et al.Mechanisms of ageing and development. 2012, Vol 133, Num 1, pp 46-49, issn 0047-6374, 4 p.Article

Novel galactosylated SLN for hepatocyte-selective targeting of floxuridinyl diacetateJIAFANG LIAN; SANQI ZHANG; JINGWEN WANG et al.Journal of drug targeting. 2008, Vol 16, Num 3, pp 250-256, issn 1061-186X, 7 p.Article

Effects of 5-Fluorouracil on Human Mitogen-activated Peripheral Blood Lymphocytes from Healthy IndividualsEISENTHAL, Avi; EYTAN, Karin; BRAZOWSKI, Eli et al.Anticancer research. 2008, Vol 28, Num 6A, pp 3785-3791, issn 0250-7005, 7 p.Article

In Vitro Activities at pH 5.0 and pH 7.0 and In Vivo Efficacy of Flucytosine against Aspergillus fumigatusVERWEIJ, Paul E; TE DORSTHORST, Debbie T. A; JANSSEN, Willem H. P et al.Antimicrobial agents and chemotherapy. 2008, Vol 52, Num 12, pp 4483-4485, issn 0066-4804, 3 p.Article

Do 5-fluorouracil therapies alter CYP2C19 metaboliser status?HELSBY, N. A; LO, W. Y; THOMPSON, P et al.Cancer chemotherapy and pharmacology. 2010, Vol 66, Num 2, pp 405-407, issn 0344-5704, 3 p.Article

Optimizing Chemotherapy Dose and Schedule by Norton-Simon Mathematical ModelingTRAINA, Tiffany A; DUGAN, Ute; HIGGINS, Brian et al.Breast disease. 2010, Vol 31, Num 1, pp 7-18, issn 0888-6008, 12 p.Article

Complete remission of a metastatic neuroendocrine tumor of the pancreas with capecitabine (Xeloda®) monotherapyFÜRSTENBERGER, Gregor; SCHMID, Peter; DUQUESNE, Ans et al.Cancer chemotherapy and pharmacology. 2008, Vol 61, Num 2, pp 347-348, issn 0344-5704, 2 p.Article

Identification of Novel Germline Polymorphisms Governing Capecitabine SensitivityO'DONNELL, Peter H; STARK, Amy L; GAMAZON, Eric R et al.Cancer. 2012, Vol 118, Num 16, pp 4063-4073, issn 0008-543X, 11 p.Article

Mutational Analysis of Flucytosine Resistance in Candida glabrataEDLIND, Thomas D; KATIYAR, Santosh K.Antimicrobial agents and chemotherapy. 2010, Vol 54, Num 11, pp 4733-4738, issn 0066-4804, 6 p.Article

Molecular Basis for the Induction of an Angiogenesis Inhibitor, Thrombospondin-1, by 5-FluorouracilZHAO, Hong-Ye; OOYAMA, Akio; FUKUSHIMA, Masakazu et al.Cancer research (Chicago, Ill.). 2008, Vol 68, Num 17, pp 7035-7041, issn 0008-5472, 7 p.Article

Severe hypertriglyceridaemia associated with the use of capecitabinePOLINDER-BOS, H. A; KOK, E. E; VAN DE WIEL, A et al.Netherlands journal of medicine. 2012, Vol 70, Num 2, pp 104-105, issn 0300-2977, 2 p.Article

The only thing I know is that I know nothing: 5-fluorouracil in human milkPECCATORI, F. A; GIOVANNETTI, E; PISTILLI, B et al.Annals of oncology. 2012, Vol 23, Num 2, pp 543-544, issn 0923-7534, 2 p.Article

Sortie de réserve hospitalière = Xéloda^®REY, Jean-Baptiste.Journal de pharmacie clinique (Paris). 2011, Vol 30, Num 2, pp 119-120, issn 0291-1981, 2 p.Article

Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK InhibitionURICK, Mary Ellen; CHUNG, Eun Joo; SHIELD, William P et al.Clinical cancer research (Print). 2011, Vol 17, Num 15, pp 5038-5047, issn 1078-0432, 10 p.Article

FUdR causes a twofold increase in the lifespan of the mitochondrial mutant gas-1VAN RAAMSDONK, Jeremy Michael; HEKIMI, Siegfried.Mechanisms of ageing and development. 2011, Vol 132, Num 10, pp 519-521, issn 0047-6374, 3 p.Article

Stability studies of capecitabineLASZCZ, M; TRZCINSKA, K; FILIP, K et al.Journal of thermal analysis and calorimetry. 2011, Vol 105, Num 3, pp 1015-1021, issn 1388-6150, 7 p.Article

Capécitabine: syndromes de Lyell et de Stevens-JohnsonLa Revue Prescrire. 2014, Vol 34, Num 365, issn 0247-7750, p. 190Article